Recent pharmacologic advancements, particularly with incretin-based therapies such as tirzepatide, a dual GIP and GLP-1 receptor agonist, have redefined the landscape of obesity management. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.